158 related articles for article (PubMed ID: 31367187)
41. Gli2 silencing enhances TRAIL-induced apoptosis and reduces tumor growth in human hepatoma cells in vivo.
Zhang DW; Li HY; Lau WY; Cao LQ; Li Y; Jiang XF; Yang XW; Xue P
Cancer Biol Ther; 2014; 15(12):1667-76. PubMed ID: 25535898
[TBL] [Abstract][Full Text] [Related]
42. Chelerythrin activates caspase-8, downregulates FLIP long and short, and overcomes resistance to tumour necrosis factor-related apoptosis-inducing ligand in KG1a cells.
Platzbecker U; Ward JL; Deeg HJ
Br J Haematol; 2003 Aug; 122(3):489-97. PubMed ID: 12877678
[TBL] [Abstract][Full Text] [Related]
43. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.
Ricci MS; Jin Z; Dews M; Yu D; Thomas-Tikhonenko A; Dicker DT; El-Deiry WS
Mol Cell Biol; 2004 Oct; 24(19):8541-55. PubMed ID: 15367674
[TBL] [Abstract][Full Text] [Related]
44. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
Zhao L; Yue P; Khuri FR; Sun SY
Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
[TBL] [Abstract][Full Text] [Related]
45. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
46. Novel phosphorylation and ubiquitination sites regulate reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP protein.
Wilkie-Grantham RP; Matsuzawa S; Reed JC
J Biol Chem; 2013 May; 288(18):12777-90. PubMed ID: 23519470
[TBL] [Abstract][Full Text] [Related]
47. Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells.
Woo SM; Min KJ; Kwon TK
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050112
[TBL] [Abstract][Full Text] [Related]
48. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
[TBL] [Abstract][Full Text] [Related]
49. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun SY
Mol Cancer; 2010 Jan; 9():23. PubMed ID: 20113484
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP.
Galligan L; Longley DB; McEwan M; Wilson TR; McLaughlin K; Johnston PG
Mol Cancer Ther; 2005 Dec; 4(12):2026-36. PubMed ID: 16373718
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
Wilson C; Wilson T; Johnston PG; Longley DB; Waugh DJ
Mol Cancer Ther; 2008 Sep; 7(9):2649-61. PubMed ID: 18790747
[TBL] [Abstract][Full Text] [Related]
52. Autophagy-Mediated Degradation of IAPs and c-FLIP(L) Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24.
Xu J; Xu X; Shi S; Wang Q; Saxton B; He W; Gou X; Jang JH; Nyunoya T; Wang X; Xing C; Zhang L; Lin Y
J Cell Biochem; 2016 May; 117(5):1136-44. PubMed ID: 26448608
[TBL] [Abstract][Full Text] [Related]
53. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5.
Kang YJ; Kim IY; Kim EH; Yoon MJ; Kim SU; Kwon TK; Choi KS
Exp Mol Med; 2011 Jan; 43(1):24-34. PubMed ID: 21150246
[TBL] [Abstract][Full Text] [Related]
54. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
55. GSK3β/ITCH/c-FLIP Axis Counteracts TRAIL-induced Apoptosis in Human Lung Adenocarcinoma Cells.
Zheng X; Huang D; Liu X; Liu QY; Gao X; Liu L
Protein Pept Lett; 2023; 30(3):242-249. PubMed ID: 36644866
[TBL] [Abstract][Full Text] [Related]
56. The SCF
Roberts JZ; Holohan C; Sessler T; Fox J; Crawford N; Riley JS; Khawaja H; Majkut J; Evergren E; Humphreys LM; Ferris J; Higgins C; Espona-Fiedler M; Moynagh P; McDade SS; Longley DB
Cell Death Differ; 2020 Sep; 27(9):2726-2741. PubMed ID: 32313199
[TBL] [Abstract][Full Text] [Related]
57. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
Seal S; Hockenbery DM; Spaulding EY; Kiem HP; Abbassi N; Deeg HJ
Exp Hematol; 2008 Dec; 36(12):1660-72. PubMed ID: 18838202
[TBL] [Abstract][Full Text] [Related]
58. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
Li W; Zhang X; Olumi AF
Cancer Res; 2007 Mar; 67(5):2247-55. PubMed ID: 17332355
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.
Kim SY; Park S; Yoo S; Rho JK; Jun ES; Chang S; Kim KK; Kim SC; Kim I
Oncotarget; 2017 Sep; 8(37):61057-61071. PubMed ID: 28977846
[TBL] [Abstract][Full Text] [Related]
60. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
